If you are an SRS member, an account has been created for you and your login credentials have been emailed to you; if you need this information resent to you, please contact the If you have any questions, please contact the SRS Education Team at email@example.com or
Click here to download abstract submission tips, tricks and FAQs.
|Abstract Submission Open||November 1, 2016|
|Abstract Submission Deadline*||February 1, 2017|
|Abstract Notification**||April 1, 2017|
|Presenter Acceptance & Registration Deadline||May 1, 2017|
*All abstracts must be submitted online by Wednesday, February 1, 2017. No exceptions will be made.
**Annual Meeting Abstract Notifications will be e-mailed on April 15, 2017.
Click here to download a complete "Call for Abstracts" brochure.
The 24th IMAST and 52nd Annual Meeting & Course will be comprised of the latest science in the field, presented as paper (podium) presentations and E-Posters (Annual Meeting Only). Presenters will represent the best of the SRS membership, as well as non-members, from an international group of physicians and researchers. The Scientific Program and E-Posters will be selected by the IMAST and Annual Meeting Program Committees, based on a blinded review of submissions.
The 2017 IMAST and Annual Meeting & Course are open to anyone involved in the treatment of spinal deformities including spine surgeons, residents and fellows, physician assistants, nurses and other allied health professionals, and researchers. The presentations selected from over 1,600 submissions will provide valuable information to all individuals caring for patients with spinal deformities.
Abstracts for both meetings must be submitted online via the SRS submission website. Complete instructions for submission are available online. Abstracts may be submitted to either the 24th IMAST, 52nd Annual Meeting or to both meetings at the same time.
All abstracts must be submitted online by Wednesday, February 1, 2017. No exceptions will be made.
All abstracts submitted will be reviewed and graded in blinded fashion by the IMAST and Annual Meeting Program Committees.
For Annual Meeting presentations, A MINIMUM (not average) two-year follow-up is required for all papers except those dealing with innovative methods. No patients with less than a two-year follow-up should be included in author data. Two-year follow-up is not required for papers submitted to IMAST.
Based upon abstract grading, those selected for the Annual Meeting will be assigned to a four-minute oral presentation or E-Poster and those selected for the IMAST meeting will be assigned to a four-minute oral presentation or two-minute oral point presentation. Due to time limitations, two-minute oral point presentations will be strictly limited to seven slides (title, introduction, methods, results (2), discussion, conclusion).
The review process takes approximately eight weeks, and acceptance notification will be made by email by approximately April 1, 2017 for IMAST and April 15, 2017 for the Annual Meeting.
Abstracts submitted to the 24th IMAST and/or 52nd Annual Meeting must fit into one of the following categories to be considered for presentation:
* Annual Meeting Only Category
Submission length is limited to 2,250 characters. Characters in the abstract title, abstract body and tables or images will be counted (including spaces). Characters in the author and institution listing will not be counted. There is a strict limit of one graph, figure or table to each submitted abstract. NO EXCEPTIONS WILL BE MADE.
ALL authors listed on an abstract will be required to submit a Financial Disclosure Statement and a FDA Disclosure during the online submission process. We require that authors disclose ALL financial relationships with medical device, pharmaceutical and/or proprietary software/database companies, not only those pertaining to the topic of the abstract. In the event that all authors on an abstract have not completed these required forms prior to the submission deadline of February 1, 2017 the abstract will NOT be reviewed or considered for inclusion in either the IMAST or Annual Meeting programs.
The questions regarding study design will be available to the reviewers and may be shown as part of the disclosure slide if the abstract is accepted for presentation. It is highly encouraged these questions be completed when submitting an abstract.
The term “hardware” should not be used in written abstract submissions, oral presentations and E-Poster presentations. The terms “instrumentation,” “implants,” “constructs,” or “montage” should be used instead.
SRS strongly prefers that pharmaceuticals and proprietary software/databases as well as surgical approaches or specific instrumentation such as “Surgimap, MIMICS, EOS Imaging, RHOTEM, Isola, TSRH, CD, XLIF, DLIF, AxiaLIF, Solera, Vertex, Expedium, Mountaineer, Shilla, VEPTR etc.,” are not used in presentations. These terms should be replaced by a generic term or description of the drug, software/database and/or instrumentation or technique unless the use of the term directly impacts learners’ understanding of the presentation or data. Instrumentation may also be referred to when the device name is a landmark system that is no longer sold (i.e. Harrington, Cotrel-Dubousset, Luque). Company names and logos must never be used in a presentation.
It is recognized that studies evaluating a product or products or comparing different products or techniques may require the use of product or technique names. If a product trade name or industry developed technique using a trademarked name are used in an abstract or presentation, the author must disclose their intent to use the term at the time of abstract submission and the abstract will be specifically reviewed by the CME Committee for evaluation of any potential conflict of interest. When there is a known potential conflict of interest, an expanded verbal disclosure will be necessary at the time of presentation. Furthermore, if a product name is mentioned, the audience should be informed of why it is necessary to give the name.
Abstracts which have been published in journals, meeting proceedings or other publication, as well as those presented at meetings prior to the SRS meeting to which authors wish to submit are NOT eligible for submission. Only abstracts that have NOT been previously published or presented are eligible for submission.
By submitting an abstract to IMAST and/or the Annual Meeting, abstract authors are agreeing that at least one author will attend the meeting(s) for which the abstract is accepted and will be available to present on the date and at the time assigned by the organizing committees. Authors will be notified of presentation times at the time of or shortly after notification of acceptance and are expected to make appropriate travel arrangements to ensure that at least one of the abstract’s authors will be in attendance. In addition, presenting authors are expected to register to attend the meetings for which they are accepted by the deadline set forth in their acceptance notification. Abstracts for which an author is not pre-registered by the dates set forth with automatically be withdrawn from the program.
All selected authors will be required to complete a formal acceptance process by May 1, 2017 for IMAST or May 15, 2017 for the Annual Meeting to confirm the invitation to participate in the program.
If an author or co-author is not able to attend the meeting to present a paper in person, it is expected that an abstract be withdrawn in advance of the meeting (by May 1, 2017 for IMAST or May 15, 2017 for the Annual Meeting) so that an alternate paper may be substituted. In the case of a “no-show” oral presentation, please note that all authors and co-authors associated with the “no-show” paper will be prohibited from presenting any papers at the next two IMAST or Annual Meetings.
At least one author or co-author on all E-Posters are expected to register to attend the meetings for which they are accepted by the deadline set forth in their acceptance notification. If this author cancels their registration prior to the meeting, the E-Poster may be withdrawn from the program.
All presentations must clear a CME review conducted by the SRS CME Committee. Presenters may be required to submit slides for review before the meeting and may be asked to make small or significant changes if a bias issue is found. Failure to address pertinent CME review issues will result in pulling the presentation from the program and in a one year ban for abstract presentations and a three-year ban for invited presentations
For more information, contact:
Scoliosis Research Society
555 E. Wells Street, Suite 1100
Milwaukee, WI 53202-3823 USA